FDA Drug Approvals, Surgery and Postsurgical Analgesia — 2021 Midyear Review

August 20, 2021

StrataGraft (allogeneic cultured keratinocytes and fibroblasts)

Allogeneic cultured keratinocytes and fibroblasts is a biologic skin substitute for grafting deep partial-thickness burns. It is an allogeneic cellularized scaffold product containing metabolically active cells that produce and secrete a variety of growth factors and cytokines that are known to be involved in wound repair and regeneration.

Approval was based on the phase 3 STRATA2016 trial. Results showed that by 3-month follow-up, durable wound closure without the need for autografting had occurred at StrataGraft treatment sites in 59 (92%) of 64 patients. Burns. 2021 Apr 23; S0305-4179(21)00110-8

Other surgery and postsurgical analgesia approvals

Zynrelef (bupivacaine/meloxicam) - New combination approved for long-acting nonopioid, noninjectable, local, postsurgical analgesia. It is indicated as a single dose for postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy, or total knee arthroplasty.

Exparel (bupivacaine liposomal) - New indication for postsurgical local analgesia expanded to include children aged 6 years and older.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.